Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FABP7 | O15540 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16554168 | 1.00 | CYP19A1 (0.50) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| SCHEMBL16373577 | 1.00 | CYP19A1 (0.50) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| SCHEMBL8131133 | 1.00 | CYP19A1 (0.50) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| SCHEMBL18630281 | 1.00 | CYP19A1 (0.50) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| SCHEMBL770738 | 1.00 | CYP19A1 (0.50) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| SCHEMBL16554167 | 1.00 | CYP19A1 (0.50) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL28986488 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL28854937 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL28854935 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL18492053 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1663 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170269-A1 | NANOPARTICLES FOR DIRECT REGULATION OF MITOCHONDRIAL GENE EXPRESSION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-05-29 | — | — | US | claimed |
| WO-2024101935-A1 | AMPHIPHILIC CONJUGATE COMPRISING SELF-ASSEMBLIYABLE PEPTIDE MOLECULE AND USE THEREOF | 울산과학기술원 | 2024-05-16 | — | — | WO | claimed |
| US-20240092849-A1 | SELECTIVE MCL-1 BINDING PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2024-03-21 | — | — | US | claimed |
| US-20240009331-A1 | UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TARGETED RADIOLABELED PEPTIDE CONJUGATES | CURASIGHT A/S (DK) | 2024-01-11 | — | — | US | claimed |
| US-20230381327-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-11-30 | — | — | US | claimed |
| EP-4255506-A1 | UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TARGETED RADIOLABELED PEPTIDE CONJUGATES | Curasight A/S (DK) | 2023-10-11 | — | — | EP | claimed |
| EP-3013340-B9 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-4225378-A1 | REACTIVE CONJUGATES | Debiopharm Research & Manufacturing S.A. (CH) | 2023-08-16 | — | — | EP | claimed |
| EP-3013340-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2023019333-A1 | MACROCYCLIC MIMETIC ANTAGONISTS WITH BIOLOGICAL ACTIVITY, USES THEREOF AND COMPOSITIONS | NOVAGEIA BIOTECNOLOGIA LTDA (BR) | 2023-02-23 | — | — | WO | claimed |
| EP-1017713-A4 | CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS | UNIV QUEENSLAND (AU) | 2002-07-24 | — | — | EP | claimed |
| CN-1353701-A | Peptidyl heterocyclic ketones useful as tryptase inhibitors | ORTHO MCNEIL PHARM INC (US) | 2002-06-12 | — | — | CN | claimed |
| EP-1017713-A1 | CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2000-07-12 | — | — | EP | claimed |
| EP-0961779-A1 | SUBSTITUTED AMINO BICYCLIC-$g(b)-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (CA) | 1999-12-08 | — | — | EP | claimed |
| WO-1999000406-A1 | CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS | THE UNIVERSITY OF QUEENSLAND (AU) | 1999-01-07 | — | — | WO | claimed |
| WO-1998032766-A1 | SUBSTITUTED AMINO BICYCLIC-β-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (US) | 1998-07-30 | — | — | WO | claimed |
| CN-1156964-A | Novel Peptides | MERCK & CO INC (US) | 1997-08-13 | — | — | CN | claimed |
| WO-1997010222-A1 | METHOD FOR PREPARING PIPERAZINES | CORTECH, INC. (US) | 1997-03-20 | — | — | WO | claimed |
| CN-1112125-A | Acyloxyhexanoic acid derivatives | CIBA GEIGY AG (CH) | 1995-11-22 | — | — | CN | claimed |
| EP-0652893-A1 | KININOGENASE INHIBITORS | SZELKE, Michael (GB) | 1995-05-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092849-A1 | SELECTIVE MCL-1 BINDING PEPTIDES | MCL1, BCL2L11, BCL2L1 | CYP19A1 4830/4885EPHX1 4709/4885NAAA 4415/4885 |
| US-20230381327-A1 | REACTIVE CONJUGATES | FCGR3B, FCGR1A, FCGR2A | CYP19A1 3539/4885EPHX1 4230/4885NAAA 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.